CINECA IRIS Institutional Research Information System

High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)

Mauro F. R.;Molica S.;Soddu S.;Ilariucci F.;Coscia M.;Zaja F.;Angelucci E.;Re F.;Liberati A. M.;Tedeschi A.;Reda G.;Pietrasanta D.;Gozzetti A.;Battistini R.;Del Poeta G.;Musolino C.;Nanni M.;Piciocchi A.;Vignetti M.;Neri A.;Albano F.;Cuneo A.;Giudice I. D.;Starza I. D.;de Propris M. S.;Raponi S.;Guarini A. R.;Foa R.

2020-01-01